Erivedge patente?

What’s Erivedge and who holds its patents?
Erivedge (sotorasib) is a small‑molecule inhibitor approved for KRAS G12C‑mutant non‑small‑cell lung cancer. The drug was developed by Amgen and its patents are owned by Amgen, with some rights licensed to other companies for specific territories. The core patents cover the compound itself, its formulation, and the method of use for KRAS‑driven cancers.

Which patents give Erivedge its legal protection?
Amgen’s portfolio includes composition‑of‑matter patents for sotorasib and its salt forms, process patents for the synthesis route, and use patents that claim the treatment of KRAS G12C tumors. The most robust patents are filed in the United States, the European Union, and other major markets.

When do the main patents expire?
The earliest expiring composition patent in the U.S. is set to lapse in 2029, while the process patents run until 2031. In the EU the expiration dates align closely, giving Amgen roughly a decade of market exclusivity before generic competition can enter.

Can biosimilars or generic versions appear before the patents run out?
Generic entry is unlikely before the final expiration because the patents covering the active ingredient and its therapeutic use remain in force. Biosimilars are not applicable for a small‑molecule drug like Erivedge, so the only route to competition is a generic that must wait until the relevant patents expire.

Why are other companies interested in Erivedge’s patents?
The KRAS G12C space is one of the fastest growing oncology targets. Competitors seek to develop alternative inhibitors or combination therapies that might infringe or challenge Amgen’s claims, especially if new mutations or resistance mechanisms arise. Licensing or cross‑licensing agreements are also a possibility to secure market share in regions where Amgen has limited presence.

What risks does Amgen face in protecting Erivedge’s patents?
Potential challenges stem from prior art that could invalidate earlier filings, or from new patents filed by rivals that overlap with Amgen’s claims. Patent litigation can be costly and may delay or limit the drug’s availability in some markets if a court issues an injunction or narrows the scope of the claims.

How does Erivedge’s patent portfolio stack up against competitors?
Compared with other KRAS inhibitors under development, Amgen’s portfolio is one of the most comprehensive. Other companies have fewer composition patents and more limited process claims, which could make them vulnerable to Amgen’s enforcement actions.

Where to find the full list of Erivedge patents and their status?
DrugPatentWatch.com provides a searchable database of active and pending patents for Erivedge, including filing dates, jurisdictions, and expiry dates. The site also tracks any recent legal actions or licensing agreements. Visit DrugPatentWatch.com – Erivedge for detailed information.

Sources
[1] DrugPatentWatch.com – Erivedge patent details.